Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.07
LH's Cash-to-Debt is ranked lower than
95% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. LH: 0.07 )
Ranked among companies with meaningful Cash-to-Debt only.
LH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.11 Max: No Debt
Current: 0.07
Equity-to-Asset 0.39
LH's Equity-to-Asset is ranked lower than
74% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. LH: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
LH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.41 Max: 0.9
Current: 0.39
0.14
0.9
Interest Coverage 6.01
LH's Interest Coverage is ranked lower than
80% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. LH: 6.01 )
Ranked among companies with meaningful Interest Coverage only.
LH' s Interest Coverage Range Over the Past 10 Years
Min: 3.63  Med: 10.84 Max: 14.88
Current: 6.01
3.63
14.88
Piotroski F-Score: 4
Altman Z-Score: 2.53
Beneish M-Score: -2.50
WACC vs ROIC
7.04%
7.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.65
LH's Operating Margin % is ranked higher than
79% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. LH: 13.65 )
Ranked among companies with meaningful Operating Margin % only.
LH' s Operating Margin % Range Over the Past 10 Years
Min: 11.48  Med: 17.58 Max: 19.94
Current: 13.65
11.48
19.94
Net Margin % 7.49
LH's Net Margin % is ranked higher than
71% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. LH: 7.49 )
Ranked among companies with meaningful Net Margin % only.
LH' s Net Margin % Range Over the Past 10 Years
Min: 5.04  Med: 10.08 Max: 11.72
Current: 7.49
5.04
11.72
ROE % 13.65
LH's ROE % is ranked higher than
75% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. LH: 13.65 )
Ranked among companies with meaningful ROE % only.
LH' s ROE % Range Over the Past 10 Years
Min: 11.27  Med: 22.19 Max: 28.64
Current: 13.65
11.27
28.64
ROA % 5.06
LH's ROA % is ranked higher than
68% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. LH: 5.06 )
Ranked among companies with meaningful ROA % only.
LH' s ROA % Range Over the Past 10 Years
Min: 4.09  Med: 8.75 Max: 11.43
Current: 5.06
4.09
11.43
ROC (Joel Greenblatt) % 52.58
LH's ROC (Joel Greenblatt) % is ranked higher than
80% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. LH: 52.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.47  Med: 104.98 Max: 138.05
Current: 52.58
54.47
138.05
3-Year Revenue Growth Rate 13.50
LH's 3-Year Revenue Growth Rate is ranked higher than
77% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. LH: 13.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.4  Med: 11.15 Max: 24.4
Current: 13.5
-21.4
24.4
3-Year EBITDA Growth Rate 8.90
LH's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. LH: 8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.65 Max: 18
Current: 8.9
0
18
3-Year EPS without NRI Growth Rate 3.90
LH's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. LH: 3.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30  Med: 15.1 Max: 82.8
Current: 3.9
-30
82.8
GuruFocus has detected 4 Warning Signs with Laboratory Corp of America Holdings $LH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LH's 10-Y Financials

Financials (Next Earnings Date: 2017-04-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LH Guru Trades in Q1 2016

Joel Greenblatt 262,389 sh (New)
David Dreman 3,169 sh (+552.06%)
Mario Gabelli 20,400 sh (+264.29%)
Jim Simons 281,805 sh (+139.82%)
Ray Dalio 28,200 sh (+56.44%)
Paul Tudor Jones 262,144 sh (+49.80%)
Wallace Weitz 777,949 sh (+11.13%)
Scott Black 20,375 sh (+4.43%)
Pioneer Investments 26,829 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
Richard Pzena Sold Out
Jana Partners Sold Out
John Paulson Sold Out
Larry Robbins 5,456,575 sh (-3.54%)
Chris Davis 1,701,662 sh (-4.34%)
Jeff Auxier 3,180 sh (-4.50%)
John Rogers 1,587,342 sh (-5.25%)
Keeley Asset Management Corp 57,675 sh (-27.13%)
Jeremy Grantham 3,900 sh (-73.47%)
Andreas Halvorsen 673,048 sh (-79.02%)
» More
Q2 2016

LH Guru Trades in Q2 2016

Wallace Weitz 805,459 sh (+3.54%)
Jeff Auxier 3,180 sh (unchged)
Pioneer Investments 26,829 sh (unchged)
Larry Robbins 5,456,575 sh (unchged)
Chris Davis Sold Out
Jeremy Grantham Sold Out
Andreas Halvorsen Sold Out
Scott Black 19,523 sh (-4.18%)
John Rogers 1,514,925 sh (-4.56%)
Paul Tudor Jones 236,880 sh (-9.64%)
Mario Gabelli 17,400 sh (-14.71%)
David Dreman 2,683 sh (-15.34%)
Keeley Asset Management Corp 47,176 sh (-18.20%)
Jim Simons 202,905 sh (-28.00%)
Ray Dalio 19,513 sh (-30.80%)
Joel Greenblatt 170,923 sh (-34.86%)
First Pacific Advisors 20,400 sh (-59.52%)
» More
Q3 2016

LH Guru Trades in Q3 2016

John Hussman 25,000 sh (New)
Richard Pzena 2,185 sh (New)
First Eagle Investment 226,794 sh (New)
Ray Dalio 30,844 sh (+58.07%)
David Dreman 2,683 sh (unchged)
First Pacific Advisors 20,400 sh (unchged)
Pioneer Investments 26,829 sh (unchged)
Wallace Weitz 766,205 sh (-4.87%)
John Rogers 1,438,798 sh (-5.03%)
Jeff Auxier 2,980 sh (-6.29%)
Keeley Asset Management Corp 43,106 sh (-8.63%)
Scott Black 17,477 sh (-10.48%)
Larry Robbins 4,212,026 sh (-22.81%)
Jim Simons 146,205 sh (-27.94%)
Joel Greenblatt 82,365 sh (-51.81%)
Mario Gabelli 5,400 sh (-68.97%)
Paul Tudor Jones 3,400 sh (-98.56%)
» More
Q4 2016

LH Guru Trades in Q4 2016

Richard Snow 16,700 sh (New)
Charles Brandes 54,221 sh (New)
Joel Greenblatt 149,653 sh (+81.69%)
First Eagle Investment 268,515 sh (+18.40%)
Richard Pzena 2,327 sh (+6.50%)
John Rogers 1,470,340 sh (+2.19%)
Wallace Weitz 778,751 sh (+1.64%)
Mario Gabelli 5,400 sh (unchged)
First Pacific Advisors 20,400 sh (unchged)
David Dreman 2,683 sh (unchged)
John Hussman Sold Out
Larry Robbins 4,188,260 sh (-0.56%)
Scott Black 17,076 sh (-2.29%)
Jeff Auxier 2,880 sh (-3.36%)
Keeley Asset Management Corp 40,406 sh (-6.26%)
Pioneer Investments 21,636 sh (-19.36%)
Paul Tudor Jones 1,800 sh (-47.06%)
Jim Simons 67,800 sh (-53.63%)
Ray Dalio 10,400 sh (-66.28%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, NYSE:DGX, OTCPK:SSMXY, NYSE:A, NYSE:Q, OTCPK:ERFSF, NAS:DXCM, NAS:QGEN, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:PRAH, OTCPK:SWTUY, NAS:CPHD, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, OTCPK:DSRLF » details
Traded in other countries:LAB.Germany,
Headquarter Location:USA
Laboratory Corp of America Holdings is a healthcare diagnostics company. The Company along with its subsidiaries provides clinical laboratory services and end-to-end drug development support.

Laboratory Corporation of America is the nation's second- largest independent clinical laboratory, with roughly 20% of the independent lab market. The company operates more than 1,800 patient-service centers, offering a broad range of clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Guru Investment Theses on Laboratory Corp of America Holdings

Wally Weitz Comments on Laboratory Corp of America - Jul 20, 2016

Laboratory Corp. of America (NYSE:LH) is a healthcare diagnostics company providing comprehensive clinical laboratory services to medical professionals and end-to-end drug development support to pharmaceutical manufacturers. LabCorp reported stronger than expected organic growth during the first quarter in both its diagnostics and drug development segments and raised its financial forecast for the full year. Covance, its drug development segment, has demonstrated improving operating momentum the past three quarters, with strength across each of its primary end markets (pre-clinical, central lab, late stage). Finally, the Center for Medicare and Medicaid Services’ (CMS’) highly anticipated Final Rule on changes to the Medicare Clinical Lab Fee Schedule in mid-June included two positives for the lab industry – a delay in implementation until 2018 and the inclusion of higher cost outpatient hospital labs, which is a piece that will determine future reimbursement levels. While final details won’t be known for some time, we anticipate these reimbursement changes will have a very modest impact on LabCorp’s future earnings power.



From Weitz Partners Fund's second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corp. of America Holdings - Apr 25, 2016

Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corporation of America Holdings - Feb 01, 2016

Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations.



From Weitz Funds' Balanced Fund fourth quarter 2015 commentary.



Check out Wallace Weitz latest stock trades

Top Ranked Articles about Laboratory Corp of America Holdings

Wally Weitz Comments on Laboratory Corp of America Guru stock highlight
Laboratory Corp. of America (NYSE:LH) is a healthcare diagnostics company providing comprehensive clinical laboratory services to medical professionals and end-to-end drug development support to pharmaceutical manufacturers. LabCorp reported stronger than expected organic growth during the first quarter in both its diagnostics and drug development segments and raised its financial forecast for the full year. Covance, its drug development segment, has demonstrated improving operating momentum the past three quarters, with strength across each of its primary end markets (pre-clinical, central lab, late stage). Finally, the Center for Medicare and Medicaid Services’ (CMS’) highly anticipated Final Rule on changes to the Medicare Clinical Lab Fee Schedule in mid-June included two positives for the lab industry – a delay in implementation until 2018 and the inclusion of higher cost outpatient hospital labs, which is a piece that will determine future reimbursement levels. While final details won’t be known for some time, we anticipate these reimbursement changes will have a very modest impact on LabCorp’s future earnings power.
From Read more...
Weitz Funds Comments on Laboratory Corp. of America Holdings Guru stock highlight
Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come. Read more...

Ratios

vs
industry
vs
history
PE Ratio 20.65
LH's PE Ratio is ranked higher than
70% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. LH: 20.65 )
Ranked among companies with meaningful PE Ratio only.
LH' s PE Ratio Range Over the Past 10 Years
Min: 13  Med: 17.21 Max: 29.28
Current: 20.65
13
29.28
Forward PE Ratio 14.99
LH's Forward PE Ratio is ranked higher than
99% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. LH: 14.99 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.65
LH's PE Ratio without NRI is ranked higher than
70% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. LH: 20.65 )
Ranked among companies with meaningful PE Ratio without NRI only.
LH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13  Med: 17.21 Max: 29.28
Current: 20.65
13
29.28
Price-to-Owner-Earnings 17.55
LH's Price-to-Owner-Earnings is ranked higher than
80% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. LH: 17.55 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.35  Med: 14.3 Max: 42.34
Current: 17.55
9.35
42.34
PB Ratio 2.68
LH's PB Ratio is ranked higher than
65% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. LH: 2.68 )
Ranked among companies with meaningful PB Ratio only.
LH' s PB Ratio Range Over the Past 10 Years
Min: 2.11  Med: 3.44 Max: 5.19
Current: 2.68
2.11
5.19
PS Ratio 1.55
LH's PS Ratio is ranked higher than
79% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. LH: 1.55 )
Ranked among companies with meaningful PS Ratio only.
LH' s PS Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.63 Max: 3
Current: 1.55
1.19
3
Price-to-Free-Cash-Flow 16.66
LH's Price-to-Free-Cash-Flow is ranked higher than
72% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. LH: 16.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.24  Med: 14.66 Max: 32.44
Current: 16.66
9.24
32.44
Price-to-Operating-Cash-Flow 12.70
LH's Price-to-Operating-Cash-Flow is ranked higher than
70% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. LH: 12.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.53  Med: 11.35 Max: 21.26
Current: 12.7
7.53
21.26
EV-to-EBIT 15.18
LH's EV-to-EBIT is ranked higher than
75% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. LH: 15.18 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 11.7 Max: 21.6
Current: 15.18
8.7
21.6
EV-to-EBITDA 11.04
LH's EV-to-EBITDA is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. LH: 11.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
LH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 9.6 Max: 16.2
Current: 11.04
7.2
16.2
PEG Ratio 2.94
LH's PEG Ratio is ranked higher than
51% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. LH: 2.94 )
Ranked among companies with meaningful PEG Ratio only.
LH' s PEG Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.56 Max: 6.31
Current: 2.94
0.86
6.31
Shiller PE Ratio 25.24
LH's Shiller PE Ratio is ranked higher than
80% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. LH: 25.24 )
Ranked among companies with meaningful Shiller PE Ratio only.
LH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.8  Med: 23.78 Max: 61.83
Current: 25.24
18.8
61.83
Current Ratio 1.36
LH's Current Ratio is ranked lower than
79% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. LH: 1.36 )
Ranked among companies with meaningful Current Ratio only.
LH' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.59 Max: 3.57
Current: 1.36
0.79
3.57
Quick Ratio 1.24
LH's Quick Ratio is ranked lower than
75% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. LH: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
LH' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.53 Max: 3.57
Current: 1.24
0.72
3.57
Days Inventory 10.99
LH's Days Inventory is ranked higher than
89% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. LH: 10.99 )
Ranked among companies with meaningful Days Inventory only.
LH' s Days Inventory Range Over the Past 10 Years
Min: 10.44  Med: 12.14 Max: 13.23
Current: 10.99
10.44
13.23
Days Sales Outstanding 50.30
LH's Days Sales Outstanding is ranked higher than
67% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. LH: 50.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.64  Med: 49.42 Max: 55.91
Current: 50.3
44.64
55.91
Days Payable 28.72
LH's Days Payable is ranked lower than
76% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. LH: 28.72 )
Ranked among companies with meaningful Days Payable only.
LH' s Days Payable Range Over the Past 10 Years
Min: 20.61  Med: 27.89 Max: 32.38
Current: 28.72
20.61
32.38

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.60
LH's 5-Year Yield-on-Cost % is ranked lower than
82% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. LH: 0.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.6
3-Year Average Share Buyback Ratio -6.30
LH's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. LH: -6.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1  Med: 1.45 Max: 6.6
Current: -6.3
-42.1
6.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.08
LH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. LH: 1.08 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 0.99 Max: 3.67
Current: 1.08
0.57
3.67
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.87
LH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
53% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. LH: 1.87 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.95
LH's Price-to-Median-PS-Value is ranked higher than
61% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. LH: 0.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.98 Max: 2.94
Current: 0.95
0.07
2.94
Price-to-Peter-Lynch-Fair-Value 3.25
LH's Price-to-Peter-Lynch-Fair-Value is ranked lower than
74% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. LH: 3.25 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LH' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.96  Med: 1.6 Max: 3.83
Current: 3.25
0.96
3.83
Earnings Yield (Greenblatt) % 6.59
LH's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. LH: 6.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.6  Med: 8.5 Max: 11.4
Current: 6.59
4.6
11.4
Forward Rate of Return (Yacktman) % 11.38
LH's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. LH: 11.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.8  Med: 18 Max: 22.6
Current: 11.38
9.8
22.6

More Statistics

Revenue (TTM) (Mil) $9,642
EPS (TTM) $ 6.94
Beta1.14
Short Percentage of Float2.68%
52-Week Range $118.35 - 146.63
Shares Outstanding (Mil)102.43

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 9,927 10,303 10,723
EPS ($) 9.55 10.08 11.02
EPS without NRI ($) 9.55 10.08 11.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.27%
Dividends per Share ($)
» More Articles for LH

Headlines

Articles On GuruFocus.com
LabCorp Stock Flat; Class-Action Lawsuit Filed for Overcharging Apr 12 2017 
5 Companies Reach Yearly Highs Apr 11 2017 
Wolf Popper LLP: Quest Diagnostics And LabCorp Sued For Excessive Charges Apr 06 2017 
Parexel Investors: Swimming With the Whales Mar 03 2017 
6 Stocks With High Business Predictability Jan 31 2017 
Chris Davis Buys Activision Blizzard, Sells Amazon.com Aug 22 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Wally Weitz Comments on Laboratory Corp of America Jul 20 2016 
Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary Jul 20 2016 

More From Other Websites
Covance to Expand Large-Molecule Development Capabilities in the UK Apr 21 2017
Will LabCorp (LH) Pull a Surprise this Earnings Season? Apr 17 2017
Class-action lawsuit claims LabCorp overcharges patients for tests Apr 10 2017
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Apr 03 2017
How much of a pay raise did LabCorp's David King get in 2016? Apr 03 2017
LabCorp Commends Reps. Dr. Bucshon, DeGette for Releasing Bipartisan Discussion Draft of the... Mar 30 2017
LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two... Mar 29 2017
Is Laboratory Corp. a Suitable Stock For Value Investors? Mar 23 2017
LabCorp (LH) Up 3.6% Since Earnings Report: Can It Continue? Mar 20 2017
College hires leader for Biotechnology Center of Excellence Mar 15 2017
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest Mar 13 2017
LabCorp is Scheduled to Present at the 2017 Barclays Global Healthcare Conference Mar 06 2017
CellNetix buys back stake from PAML ahead of LabCorp deal Mar 03 2017
Post Earnings Coverage as Quintiles IMS' Q4 Bottom-line Beat Market Estimates Mar 03 2017
LabCorp is Scheduled to Present at the 38th Annual Raymond James Institutional Investors Conference Mar 01 2017
LabCorp to buy 1,600-employee Washington firm Feb 23 2017
LabCorp to Acquire Pathology Associates Medical Laboratories from Providence Health & Services and... Feb 23 2017
Medford's Seventh Sense wins narrow FDA approval for blood-collection device Feb 23 2017
Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: 2016 By the Numbers : February 21,... Feb 21 2017
Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: Q4, 2016 By the Numbers : February... Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)